CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/06/25
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/04/25
CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewsWire • 10/30/25
CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/25
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025GlobeNewsWire • 07/31/25
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic MelanomaGlobeNewsWire • 05/19/25
CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)Seeking Alpha • 05/12/25